NDAORALTABLET
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
61
Mechanism of Action
Phosphodiesterase 4 Inhibitors
Pharmacologic Class:
Phosphodiesterase 4 Inhibitor
Clinical Trials (5)
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
Started Jun 2025
Adherence to Otezla
Started Jun 2025
0Psoriasis
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Started Nov 2023
203 enrolled
Plaque Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Started Oct 2023
51 enrolled
Plaque Psoriasis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Started Mar 2023
48 enrolled
Behçet's DiseaseJuvenile Psoriatic Arthritis
Loss of Exclusivity
LOE Date
Nov 29, 2034
106 months away
Patent Expiry
Nov 29, 2034
Exclusivity Expiry
Oct 25, 2027
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7427638 | Feb 16, 2028 | SubstanceProduct | — |
| 7427638*PED | Aug 16, 2028 | — | |
| 10092541 | May 29, 2034 | U-2403 | |
| 9872854 | May 29, 2034 | U-2233 | |
| 10092541*PED | Nov 29, 2034 | — |